Division of Nephrology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China.
Biomarkers. 2011 Mar;16(2):129-35. doi: 10.3109/1354750X.2010.535172. Epub 2010 Dec 6.
Advanced oxidation protein products (AOPP) is widely used as a uremic biomarker, especially for cardiovascular disease. However, it has not been determined whether it is better to measure AOPP in plasma or serum. In this cross-sectional study, which included 102 patients undergoing maintenance hemodialysis, fibrinogen-free serum and defibrinated plasma samples were prepared. AOPP levels from fibrinogen-free samples displayed a stronger correlation with myeloperoxidase activity and levels of C-reactive protein, interleukin-6 and tumor necrosis factor-alpha, as well as prevalent cardiovascular disease, than AOPP levels obtained from plasma samples. These results demonstrated that fibrinogen interferes with the measurement of AOPP.
晚期氧化蛋白产物（AOPP）被广泛用作尿毒症生物标志物，尤其适用于心血管疾病。然而，目前尚不确定在血浆或血清中测量 AOPP 哪种方法更好。在这项纳入 102 例维持性血液透析患者的横断面研究中，制备了无纤维蛋白原血清和去纤维蛋白血浆样本。与来自血浆样本的 AOPP 水平相比，无纤维蛋白原样本的 AOPP 水平与髓过氧化物酶活性以及 C 反应蛋白、白细胞介素-6 和肿瘤坏死因子-α水平，以及普遍存在的心血管疾病相关性更强。这些结果表明纤维蛋白原会干扰 AOPP 的测量。
